What are the diagnostic workup, laboratory tests, and treatment options for a newly diagnosed hepatocellular carcinoma?

Hepatocellular Carcinoma: Diagnosis, Laboratory Tests, and Treatment

Diagnostic Workup

For newly diagnosed HCC, diagnosis is established through either characteristic imaging findings on multiphasic CT/MRI or tissue biopsy, with imaging alone being sufficient in cirrhotic patients showing the typical vascular pattern. 1

Imaging-Based Diagnosis (Non-Invasive)

In cirrhotic patients only, HCC can be diagnosed without biopsy using:

• Multiphasic multidetector CT or dynamic contrast-enhanced MRI showing the characteristic vascular hallmark:
  • Arterial phase: hypervascular enhancement (stronger than surrounding liver)
  • Portal venous/delayed phase: washout (hypodensity compared to surrounding liver) 1

This imaging pattern has 96-100% specificity though only ~60% sensitivity 2. MRI offers moderately higher sensitivity than CT 3.

Critical caveat: Non-invasive criteria apply only to cirrhotic patients and those with chronic hepatitis B. Do not use these criteria in non-cirrhotic livers without hepatitis B 1.

When Biopsy is Required

Biopsy is indicated when:

• Imaging is atypical or inconclusive
• Patient is non-cirrhotic (except chronic HBV)
• Differentiation from cholangiocarcinoma is needed 1

Avoid biopsy in three situations:

1. Patient unsuitable for any therapy due to comorbidity
2. Decompensated cirrhosis with patient already listed for transplant
3. Patient is resection candidate with acceptable surgical risk 1

Important warning: Tumor seeding occurs in 0-11% of biopsies, with median time to seeding of 17 months 1.

Laboratory Tests

Serum Markers

• Alpha-fetoprotein (AFP): May be helpful for monitoring but should not be used as the sole determinant for treatment decisions 1. AFP lacks adequate sensitivity and specificity for diagnosis 4.

• Des-gamma carboxy prothrombin (DCP): Can improve diagnostic accuracy when combined with AFP 5

Liver Function Assessment

Child-Pugh scoring is mandatory, evaluating:

• Bilirubin
• Albumin
• Ascites
• Prothrombin time
• Hepatic encephalopathy 1

Portal Hypertension Assessment

Evaluate for:

• Esophageal varices
• Splenomegaly with platelets <100,000/μL
• Hepatic venous pressure gradient >10 mmHg (if measured) 1

Staging Workup

Complete staging requires:

• Contrast-enhanced MRI or helical CT of liver (tumor extent)
• Chest CT (for metastases in advanced disease)
• Bone scan if symptomatic (advanced disease)
• Performance status assessment 1

Staging System

Use the Barcelona Clinic Liver Cancer (BCLC) staging system for all HCC patients with cirrhosis 1. This system links stage directly to treatment options:

• Stage 0 (Very Early): Single tumor <2 cm
• Stage A (Early): Single tumor <5 cm OR up to 3 nodules <3 cm
• Stage B (Intermediate): Multinodular, asymptomatic, no vascular invasion/extrahepatic spread
• Stage C (Advanced): Portal invasion, nodal involvement, or metastases with PS 1-2
• Stage D (Terminal): Heavily impaired liver function or PS >2

Treatment Algorithm

Curative Treatments (BCLC Stage 0 and A)

1. Surgical Resection

• Non-cirrhotic patients: Resection is recommended if R0 resection achievable without causing liver failure 1

• Cirrhotic patients: Resection only if:

  • Single lesion
  • Child-Pugh A
  • Good performance status
  • No clinically significant portal hypertension
  • Postoperative mortality <5% 1

2. Radiofrequency Ablation (RFA)

• Preferred for: Single nodule <2 cm (BCLC stage 0) or early stages unsuitable for resection 1
• RFA is superior to percutaneous ethanol injection (PEI), especially for tumors >2 cm 1
• Maximum parameters: ≤5 lesions, each ≤5 cm diameter 1

3. Liver Transplantation

• Indicated for: Solitary lesion <5 cm OR up to 3 nodules <3 cm (Milan criteria) when unsuitable for resection 1
• If waiting time >6 months: offer resection, RFA, or TACE as bridge therapy 1

Critical point: Neo-adjuvant or adjuvant therapies are not recommended after resection or ablation 1

Palliative Treatments

BCLC Stage B (Intermediate)

Transarterial chemoembolization (TACE) is the standard treatment 1:

• For multinodular asymptomatic tumors
• Excellent liver function required
• No macroscopic vascular invasion or extrahepatic spread
• Use doxorubicin-eluting beads to minimize systemic toxicity 1

BCLC Stage C (Advanced)

Sorafenib is the standard systemic therapy for 1:

• Advanced HCC with well-preserved liver function (Child-Pugh A)
• Intermediate stage HCC progressing after TACE

Do not use outside clinical trials:

• Systemic chemotherapy
• Tamoxifen
• Immunotherapy (note: this is 2012 guideline; newer immunotherapy data exists)
• Anti-androgens
• Somatostatin analogues 1

Alternative considerations:

• Y-90 radioembolization: May be competitive with sorafenib/TACE in select patients with prior TACE failure, excellent liver function, macrovascular invasion without extrahepatic disease 1
• External beam radiotherapy: For bone metastases pain control 1

BCLC Stage D (Terminal)

Only symptomatic/supportive care 1

Response Evaluation and Follow-Up

Imaging Surveillance

Use dynamic CT or MRI with modified RECIST (mRECIST) criteria measuring viable tumor (arterial enhancement) rather than total tumor size 1

Follow-up schedule:

• After curative treatment (resection/RFA):

  • Every 3 months for first 2 years
  • Every 6 months thereafter
  • Assess for liver decompensation and recurrence 1

• During palliative treatment (TACE/sorafenib):

  • Every 2 months
  • Assess for liver decompensation and tumor progression 1

Monitoring Parameters

• Clinical evaluation for liver decompensation
• AFP levels (adjunctive, not sole determinant) 1
• Viable tumor defined as contrast uptake in arterial phase 1

Common Pitfalls to Avoid

1. Do not use non-invasive imaging criteria in non-cirrhotic patients (except chronic HBV)
2. Do not rely on AFP alone for diagnosis or treatment decisions
3. Do not perform resection in cirrhotic patients with portal hypertension - high decompensation risk
4. Do not combine TACE with sorafenib outside clinical trials
5. Do not use contrast-enhanced ultrasound alone for diagnosis - can mimic cholangiocarcinoma
6. Do not measure total tumor diameter - use mRECIST measuring only viable (enhancing) tumor

This algorithmic approach prioritizes mortality and quality of life outcomes, with treatment selection based on tumor stage, liver function, and performance status rather than tumor characteristics alone.